A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia
Trial · NCT04308096
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of subjects for each adverse events | up to week 140 | |
| Primary | Effect to Body temperature | up to week 140 | |
| Primary | Effect to Pulse rate | up to week 140 | |
| Primary | Effect to Respiratory rate | up to week 140 | |
| Primary | Effect to Systolic blood pressure in sitting position | up to week 140 | |
| Primary | Effect to Diastolic blood pressure in sitting position | up to week 140 | |
| Primary | Effect to 12-lead electrocardiogram (ECG) | up to week 140 | The presence of abnormality in the electrocardiogram |
| Primary | Effect to renal ultrasound | up to week 140 | The evaluation to nephrocalcinosis in five grades by renal ultrasound |
| Primary | Effect to Echocardiogram | up to week 140 | The presence of ectopic calcification in the heart by Echocardiogram |
| Secondary | Concentration of serum phosphorus | up to week 140 | |
| Secondary | Concentration of serum 1,25(OH)2D | up to week 140 | |
| Secondary | Concentration of urinary phosphorus | up to week 140 | |
| Secondary | Concentration of tubular resorption of phosphorus（TRP） | up to week 140 | |
| Secondary | Concentration of maximum tubular reabsorption of phosphate/glomerular filtration rate (TmP/GFR) | up to week 140 | |
| Secondary | concentration of Carboxy terminal cross-linked telopeptide of type 1 collagen (CTx) (Adult patients with XLH) | up to week 140 | |
| Secondary | concentration of Procollagen type 1 N-propeptide (P1NP) (Adult patients with XLH) | up to week 140 | |
| Secondary | concentration of Bone-specific alkaline phosphatase (BALP)(Adult patients with XLH) | up to week 140 | |
| Secondary | Concentration of serum alkaline phosphatase (ALP) (Pediatric patients with XLH) | up to week 140 | |
| Secondary | Motor functions (6 minutes walk test (6MWT)) | up to week 140 | |
| Secondary | Radiographic findings of fracture and enthesopathy (Adult patients with XLH) | up to week 140 | The presence of radiographic fracture and enthesopathy assessed by X-ray (Adult patients with XLH) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04308096/registered